Cargando…
Neurological immunotherapy in the era of COVID-19 — looking for consensus in the literature
The coronavirus disease 2019 (COVID-19) pandemic is concerning for patients with neuroimmunological diseases who are receiving immunotherapy. Uncertainty remains about whether immunotherapies increase the risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or increase...
Autores principales: | Korsukewitz, Catharina, Reddel, Stephen W., Bar-Or, Amit, Wiendl, Heinz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7341707/ https://www.ncbi.nlm.nih.gov/pubmed/32641860 http://dx.doi.org/10.1038/s41582-020-0385-8 |
Ejemplares similares
-
Author Correction: Neurological immunotherapy in the era of COVID-19 — looking for consensus in the literature
por: Korsukewitz, Catharina, et al.
Publicado: (2020) -
MS-Versorgung heute und Vision für die Zukunft - eine Rolle für die ASV?
por: Korsukewitz, Catharina, et al.
Publicado: (2022) -
Dichoptic Metacontrast Masking Functions to Infer Transmission Delay in Optic Neuritis
por: Bruchmann, Maximilian, et al.
Publicado: (2016) -
Therapeutic Antibodies in Neurological Diseases: Witnessing the Continuation of the Impressive Success in Neuro-Immunotherapies
por: Dalakas, Marinos C., et al.
Publicado: (2022) -
Neurological telemedicine in the COVID-19 era
por: Patterson, Victor
Publicado: (2020)